基于结构的新型抗癌去甲异喹啉拓扑异构酶 I 抑制剂的设计、合成与生物学研究。
Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors.
机构信息
Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmaceutical Sciences, and the Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, USA.
出版信息
J Med Chem. 2010 Mar 11;53(5):1979-89. doi: 10.1021/jm901649x.
Abstract
On the basis of the superimposition of the crystal structures of norindenoisoquinoline 5 and topotecan (2) bound in the topoisomerase I-DNA covalent complex, as well as molecular docking and quantum chemical calculations, the substituted norindenoisoquinoline 14a was designed by transporting the 9-dimethylaminomethyl group of topotecan to the 10-position of the norindenoisoquinoline 5. The desired compound 14a was synthesized and found to possess topoisomerase I inhibitory activity that was slightly better than that of the starting compound 5. A focused set of 10-substitued norindenoisoquinoline analogues were then synthesized. The imidazole-substituted compound 14c was highly cytotoxic when evaluated in a series of human leukemia, ovarian, and breast cancer cells.
摘要
基于与拓扑异构酶 I-DNA 共价复合物结合的去甲异喹啉酮 5 和拓扑替康（2）的晶体结构叠加，以及分子对接和量子化学计算，通过将拓扑替康的 9-二甲氨基甲基基团转移到去甲异喹啉酮 5 的 10 位，设计了取代的去甲异喹啉酮 14a。合成了所需的化合物 14a，并发现其具有拓扑异构酶 I 抑制活性，略优于起始化合物 5。然后合成了一组 10 位取代的去甲异喹啉酮类似物。在一系列人白血病、卵巢和乳腺癌细胞中评估时，咪唑取代的化合物 14c 具有很高的细胞毒性。
相似文献
1
Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors.基于结构的新型抗癌去甲异喹啉拓扑异构酶 I 抑制剂的设计、合成与生物学研究。
J Med Chem. 2010 Mar 11;53(5):1979-89. doi: 10.1021/jm901649x.
2
A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.对硝化茚并异喹啉的系统研究揭示了一种有效的拓扑异构酶I抑制剂。
J Med Chem. 2006 Dec 28;49(26):7740-53. doi: 10.1021/jm060974n.
3
Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.双茚并异喹啉作为拓扑异构酶I抑制剂的合成及生物学评价
J Med Chem. 2006 Aug 24;49(17):5129-40. doi: 10.1021/jm060046o.
4
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.一种新型的去甲茚并异喹啉结构揭示了拓扑异构酶I-DNA共价复合物三元捕获的常见界面抑制剂模式。
Mol Cancer Ther. 2006 Feb;5(2):287-95. doi: 10.1158/1535-7163.MCT-05-0456.
5
Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.新型茚并[1,2-c]异喹啉的合成：细胞毒性非喜树碱类拓扑异构酶I抑制剂
J Med Chem. 2000 Oct 5;43(20):3688-98. doi: 10.1021/jm000029d.
6
Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents: a systematic study of structure-activity relationships.吖啶并异喹啉类作为拓扑异构酶 I 抑制剂和潜在的抗癌剂：构效关系的系统研究。
J Med Chem. 2012 Feb 23;55(4):1682-97. doi: 10.1021/jm201512x. Epub 2012 Feb 13.
7
Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.茚并异喹啉拓扑异构酶I抑制剂中茚酮环的优化
J Med Chem. 2007 Sep 6;50(18):4388-404. doi: 10.1021/jm070307+. Epub 2007 Aug 4.
8
Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.发现不含3-硝基毒性基团的强效茚并异喹啉拓扑异构酶I抑制剂。
J Med Chem. 2015 May 14;58(9):3997-4015. doi: 10.1021/acs.jmedchem.5b00303. Epub 2015 Apr 24.
9
Synthesis of new 3-arylisoquinolinamines: effect on topoisomerase I inhibition and cytotoxicity.新型3-芳基异喹啉胺的合成：对拓扑异构酶I抑制作用及细胞毒性的影响
Bioorg Med Chem Lett. 2003 Dec 15;13(24):4451-4. doi: 10.1016/j.bmcl.2003.09.001.
10
Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).吲哚异喹啉类抑制剂的合成与生物评价，该抑制剂既能抑制酪氨酰-DNA 磷酸二酯酶 I（Tdp1），又能抑制拓扑异构酶 I（Top1）。
J Med Chem. 2013 Jan 10;56(1):182-200. doi: 10.1021/jm3014458. Epub 2012 Dec 21.
引用本文的文献
1
Design, Synthesis and Bioactive Evaluation of Topo I/ Dual Inhibitors to Inhibit Oral Cancer via Regulating the PI3K/AKT/NF-κB Signaling Pathway.通过调节PI3K/AKT/NF-κB信号通路抑制口腔癌的拓扑异构酶I/双重抑制剂的设计、合成及生物活性评价
Molecules. 2025 Feb 14;30(4):894. doi: 10.3390/molecules30040894.
2
Imidazoles as potential anticancer agents.咪唑类作为潜在的抗癌药物。
Medchemcomm. 2017 Apr 13;8(9):1742-1773. doi: 10.1039/c7md00067g. eCollection 2017 Sep 1.
3
Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.基于天然产物虚拟筛选的低细胞毒性DNA拓扑异构酶I抑制剂的发现
Mar Drugs. 2017 Jul 9;15(7):217. doi: 10.3390/md15070217.
4
Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors.6-取代中氮茚并喹啉二酮作为催化性DNA拓扑异构酶I抑制剂的合成与生物学评价
Eur J Med Chem. 2015 Aug 28;101:525-33. doi: 10.1016/j.ejmech.2015.07.007. Epub 2015 Jul 8.
5
Solvent dependency of the UV-Vis spectrum of indenoisoquinolines: role of keto-oxygens as polarity interaction probes.茚并异喹啉的 UV-Vis 光谱的溶剂依赖性：酮氧作为极性相互作用探针的作用。
PLoS One. 2013 Sep 26;8(9):e73881. doi: 10.1371/journal.pone.0073881. eCollection 2013.
6
Discovery of indeno[1, 2 - c] quinoline derivatives as dual topoisomerases I/II inhibitors: part 3.吲哚并[1,2-c]喹啉衍生物作为拓扑异构酶 I/II 双重抑制剂的发现：第 3 部分。
Mol Divers. 2013 Nov;17(4):781-799. doi: 10.1007/s11030-013-9475-5.
7
DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.结直肠癌中的 DNA 损伤反应途径和细胞周期检查点：靶向治疗的当前概念和未来展望。
Curr Cancer Drug Targets. 2012 May;12(4):356-71. doi: 10.2174/156800912800190901.
8
Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.探索 DNA 拓扑异构酶 I 配体空间，寻找新型抗癌药物。
PLoS One. 2011;6(9):e25150. doi: 10.1371/journal.pone.0025150. Epub 2011 Sep 22.
本文引用的文献
1
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.DNA拓扑异构酶I抑制剂：化学、生物学及界面抑制
Chem Rev. 2009 Jul;109(7):2894-902. doi: 10.1021/cr900097c.
2
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.吲哚并异喹啉类非喜树碱拓扑异构酶 I 抑制剂：最新研究进展及展望。
Mol Cancer Ther. 2009 May;8(5):1008-14. doi: 10.1158/1535-7163.MCT-08-0706. Epub 2009 Apr 21.
3
DNA cleavage assay for the identification of topoisomerase I inhibitors.用于鉴定拓扑异构酶I抑制剂的DNA切割试验
Nat Protoc. 2008;3(11):1736-50. doi: 10.1038/nprot.2008.174.
4
The binding orientation of a norindenoisoquinoline in the topoisomerase I-DNA cleavage complex is primarily governed by pi-pi stacking interactions.氮茚异喹啉在拓扑异构酶I-DNA切割复合物中的结合取向主要由π-π堆积相互作用决定。
J Phys Chem B. 2008 Aug 7;112(31):9484-9. doi: 10.1021/jp8005603. Epub 2008 Jul 18.
5
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.下一代拓扑异构酶I抑制剂：原理与生物标志物策略。
Biochem Pharmacol. 2008 Mar 15;75(6):1262-71. doi: 10.1016/j.bcp.2007.10.016. Epub 2007 Oct 22.
6
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.新型茚并异喹啉类化合物NSC 725776和NSC 724998可产生持续的拓扑异构酶I切割复合物并克服多药耐药性。
Cancer Res. 2007 Nov 1;67(21):10397-405. doi: 10.1158/0008-5472.CAN-07-0938.
7
Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.硝化茚并异喹啉类作为拓扑异构酶I抑制剂：一项系统性研究与优化
J Med Chem. 2007 Sep 6;50(18):4419-30. doi: 10.1021/jm070361q. Epub 2007 Aug 15.
8
Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.茚并异喹啉拓扑异构酶I抑制剂中茚酮环的优化
J Med Chem. 2007 Sep 6;50(18):4388-404. doi: 10.1021/jm070307+. Epub 2007 Aug 4.
9
Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.在人类癌细胞培养物中，对实现最佳茚并异喹啉拓扑异构酶I抑制作用及细胞毒性所需的内酰胺侧链长度进行研究。
J Med Chem. 2007 May 3;50(9):2040-8. doi: 10.1021/jm0613119. Epub 2007 Apr 3.
10
A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.对硝化茚并异喹啉的系统研究揭示了一种有效的拓扑异构酶I抑制剂。
J Med Chem. 2006 Dec 28;49(26):7740-53. doi: 10.1021/jm060974n.
Zotero 插件